Qva149 Is More Efficacious Than Tiotropium And Salmeterol/Fluticasone Combination (Sfc) In Improving Patient-Reported Outcomes And Lung Function In Copd Patients With Moderate To Severe Baseline Dyspnoea: The Ignite Trials

Introduction: QVA149 is an approved once-daily dual bronchodilator for maintenance treatment of patients with COPD. Here, we assessed the efficacy of QVA149 in improving dyspnoea, health status and lung function in COPD patients with moderate-to-severe baseline dyspnoea (GOLD Group B) from SHINE and ILLUMINATE studies. Methods: Symptomatic patients from SHINE (N=2144) and ILLUMINATE (N=523) studies with baseline dyspnoea index (BDI) ≤7 (moderate-to-severe dyspnoea equivalent to GOLD Group B) were included in this subgroup analysis. QVA149 was compared to placebo (PBO), open-label tiotropium (TIO), and SFC; TDI, SGRQ and lung function (trough and pre-dose FEV 1 ) were assessed at Week 26. Results: Mean BDI was comparable in both SHINE [QVA149 (n=305): 5.44, TIO (n=313): 5.57, PBO (n=131): 5.47] and ILLUMINATE [QVA149 (n=166): 5.78, SFC (n=179): 5.85] studies. QVA149 provided significant improvement in dyspnoea and lung function, compared with PBO, TIO and SFC (Table). QVA149 also improved (not significant) SGRQ total score versus SFC. Conclusion: In patients with moderate-to-severe baseline dyspnoea (comparable to GOLD Group B), QVA149 was more efficacious than TIO and SFC in improving patient-reported outcomes and lung function.